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Four months have passed since the World Health Organization (WHO) declares the coronavirus disease 2019 (COVID-19) as global pandemic disease. The number of positive and death cases from COVID-19 is still increasing. The manifestation of COVID-19 range from mild respiratory symptoms such as fever and cough to severe and potentially lethal symptoms such as sepsis, arrhythmia, heart failure, and loss of consciousness \[[@bib1]\]. Several comorbid conditions, including dyslipidemia, have been identified to be associated with the development of severe outcomes from COVID-19 \[[@bib2]\]. One of the drugs most commonly taken by patients with dyslipidemia is a statin. Statin is an HMG-CoA reductase inhibitor that has been long known as an effective cholesterol-lowering agent. Several articles have proposed that statin may be beneficial in improving the outcome of COVID-19 \[[@bib3],[@bib4]\]. The beneficial effects of statin may be related to its pleiotropic properties. This pleiotropic property of statin is believed to reduce the burden of obesity, cardiovascular disease, and dyslipidemia which are associated with poor outcomes of COVID-19. The pleiotropic effect of statin can down-regulate the CD147 in human cells, including pulmonary cells, therefore can impair the virus's ability to infect cells and reducing its infectivity \[[@bib3]\]. Statin can also prevent or reverse host cell lipid raft alterations induced by COVID-19 infection, which can reduce both cell infection and viral replication. Moreover, pleiotropic properties of statin can exert anti-inflammatory effects by inhibiting NLRP3 inflammasome through the TLR4/MyD88/NF-κB pathway, therefore restraining the uncontrolled inflammation which can be fatal in COVID-19 patients \[[@bib3]\]. In silico study by Reiner et al. \[[@bib4]\] showed that statin may be an effective SARS-CoV-2 Mpro inhibitors based on its binding energy which is higher than protease or polymerase inhibitors. However, all of these arguments are not yet supported by sufficient in human studies. This study aims to analyze the association between statin use and in-hospital outcomes from COVID-19 infection.

2. Methods {#sec2}
==========

We conducted a systematic search of the literature on Google scholar using the keywords \"statin\" OR \"lipid-lowering drugs\" OR \"lipid-lowering agents\" AND \"coronavirus disease 2019\" OR \"COVID-19\", until the present time (August 1st, 2020) with language restricted to English only. The title, abstract, and full text of all articles identified that matched the search criteria were assessed, and those reporting the rate of metformin use in COVID-19 patients with a clinically validated definition of "severe disease" and \"mortality\" were included in this meta-analysis. The references of all identified studies were also analyzed (forward and backward citation tracking) to identify other potentially eligible articles.

A meta-analysis was performed using Review Manager 5.4 (Cochrane Collaboration) software. Dichotomous variables were calculated using the Mantel-Haenszel formula with fixed-effects models, but we would switch to random-effects models if significant heterogeneity was found. We used the I^2^ statistic to assess the heterogeneity, value of \<25%, 26--50%, and \>50% considered as low, moderate, and high degrees of heterogeneity, respectively. The effect estimate was reported as odds ratio (OR) along with its 95% confidence intervals (CIs) for dichotomous variables, respectively. P-value was two-tailed, and the statistical significance set at ≤0.05.

3. Results {#sec3}
==========

A total of 8350 records were obtained through systematic electronic searches and other ways. After screening titles, abstracts, and full texts, 9 studies \[[@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13]\] with a total of 3449 COVID-19 patients were included in the meta-analysis. The essential characteristics of the included studies are summarized in [Table 1](#tbl1){ref-type="table"} . The individual and pooled ORs for the association between statin use and severe outcome of COVID-19 is shown in [Fig. 1](#fig1){ref-type="fig"} A, while the association between statin use and mortality rate from COVID-19 is shown in [Fig. 1](#fig1){ref-type="fig"}B. Our pooled analysis showed that statin use did not improve severity outcome \[OR 1.64 (95% CI 0.51--5.23), *p* = 0.41, *I* ^2^ = 93%, random-effect modelling\] nor mortality rate from COVID-19 infection \[OR 0.78 (95% CI 0.50--1.21), *p* = 0.26, *I* ^2^ = 0%, fixed-effect modelling\].Table 1Characteristics of included studies.Table 1StudySample sizeDesignAge (years)OutcomeStatin medicationTaking (n)Not taking (n)Argenziano et al. \[[@bib5]\] 20201000Case-series62.6 ± 18.5Severity361 (36.1%)639 (63.9%)Ayed et al. \[[@bib6]\] 2020103Retrospective cohort53.3 ± 14.1Mortality10 (9.7%)93 (90.3%)De Spiegeller et al. \[[@bib7]\] 2020154Retrospective cohort85.9 ± 7.2Severity31 (20.1%)123 (79.9%)Dreher et al. \[[@bib8]\] 202050Retrospective cohort66.3 ± 13.3Severity18 (36%)32 (64%)Nguyen et al. \[[@bib9]\] 2020356Retrospective cohort61.3 ± 17Mortality90 (25.2%)266 (74.8%)Rodriguez-Nava et al. \[[@bib10]\] 202087Retrospective cohort67 ± 12.5Mortality47 (54%)40 (46%)Wang et al. \[[@bib11]\] 202058Retrospective cohort67 ± 12.5Mortality27 (46.5%)31 (53.5%)Yan et al. \[[@bib12]\] 2020610Case-control48.7 ± 14.1Severity77 (12.6%)533 (87.4%)Zeng et al. \[[@bib13]\] 20201031Retrospective cohort60.3 ± 14.3Mortality38 (3.6%)993 (96.4%)Fig. 1Forest plot that demonstrates the association of statin use with the severe outcome (A) and mortality rate (B) from COVID-19 infection.Fig. 1

4. Discussion {#sec4}
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Based on our meta-analysis of available data, statin use did not improve severity outcomes and mortality from COVID-19 infection. Several reasons can be proposed to explain this result. First, apart from its beneficial effects through pleiotropic properties, the action of statin on TLR and NF-κB signaling also carry the potential risk of exacerbating compensatory immune signals and poor disease outcome \[[@bib14]\]. This theory is supported by a retrospective analysis of the findings from a multicenter clinical trial on the efficacy of rosuvastatin against infection-induced ARDS that showed higher IL-18 levels and mortality in statin-treated patients \[[@bib15]\]. Second, statin may cause myotoxicity in some patients that can cause acute kidney injury. Moreover, this adverse effect of statin may be exacerbated when given concomitantly with antiviral agents for COVID-19 such as lopinavir and darunavir. Statins are a substrate for cytochrome P450 (CYP) system, especially 3A isoenzymes and P-glycoproteins (P-gp), while protease inhibitors, such as lopinavir and darunavir are potent inhibitors of both CYP3A and P-gp, so their concomitant administration will result in markedly statin exposure and adverse effects \[[@bib14]\]. Therefore, the beneficial effects of statin may be counter-balanced by its potentially harmful effects and causing a neutral effect toward COVID-19. Finally, the anti-inflammatory effects of statin are relatively lower than corticosteroids \[[@bib16]\], making statin cannot make a significant alteration in the inflammation or cytokine storm that happened in COVID-19, thus the in-hospital outcome of COVID-19 was not altered by statin administration.

Patients with dyslipidemia should hence be advised to continue taking statin during the COVID-19 pandemic given its potential benefit in reducing the cardiovascular outcomes and its neutral effects toward COVID-19 outcomes. Physicians should also still giving statin into the regime of their dyslipidemic patients' treatment if the patients have not been given it yet.

This study has several limitations. First, the presence of confounding factors such as age, other comorbid conditions of patients, and other medications that are taken by patients that can affect the relationship between statin and in-hospital outcomes of COVID-19 shall still be considered. Second, no study states the information regarding dosage and duration of statin treatment in their studied samples that can give rise to bias in this study, given that statin must be given at the right dose and sufficient duration of treatment to exert its pleiotropic effects. We hope that this study can give further insight into statin therapy in COVID-19 patients.
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